The non-ASCT strategy was based upon prior experience from MSKCC showing similar outcomes for HR-NB patients managed with dose-intensive induction regimens, anti-GD2 plus GM-CSF based immunotherapy, and RT to the primary site (Kushner et al., 2016). The gene discussed is CSF2; the disease is neuroblastoma.